LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
Hospital Universitario La Paz
Madrid, EspañaHospital Universitario La Paz-ko ikertzaileekin lankidetzan egindako argitalpenak (24)
2024
-
Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach
Archives of pathology & laboratory medicine, Vol. 148, Núm. 3, pp. 318-326
-
RET Fusion Testing in Patients With NSCLC: The RETING Study
JTO Clinical and Research Reports, Vol. 5, Núm. 4
-
The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium
Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 352-362
2022
-
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism
Nature medicine, Vol. 28, Núm. 4, pp. 752-765
2021
-
Overview of virus and cancer relationships. Position paper
Revista Espanola de Quimioterapia, Vol. 34, Núm. 6, pp. 525-555
2020
-
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus
Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 759-771
2019
-
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study
Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132
2018
-
Analysis of response rate with ANTI-PD1/PDL-1 monoclonal antibodies in advanced solid tumors: A meta-analysis of randomized clinical trials
Oncotarget, Vol. 9, Núm. 9, pp. 8706-8715
-
Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer
European Respiratory Journal
2017
-
A consensus statement on the gender perspective in lung cancer
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 527-535
-
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
New England Journal of Medicine, Vol. 377, Núm. 20, pp. 1919-1929
-
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy
Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 219-226
2015
-
Actualización de las recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón avanzado de célula no pequeña. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Españ
Revista Espanola de Patologia
-
Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial
JAMA Oncology, Vol. 1, Núm. 2, pp. 149-157
-
Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer
Journal of Cancer Research and Clinical Oncology, Vol. 141, Núm. 1, pp. 43-53
2014
-
Accurate identification of ALK positive lung carcinoma patients: Novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry
PLoS ONE, Vol. 9, Núm. 9
-
Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 17, Núm. 2, pp. 103-112
2013
-
DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: Implications for outcomes and histologic classification
Carcinogenesis, Vol. 34, Núm. 5, pp. 1031-1038
2012
-
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial
The Lancet Oncology, Vol. 13, Núm. 3, pp. 239-246
-
Guidelines for biomarker testing in advanced non-small-cell lung cancer. A National Consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)
Clinical and Translational Oncology, Vol. 14, Núm. 5, pp. 338-349